Fertility Startup Revitalizes Human Eggs to Improve Conception Odds
▼ Summary
– Ovo Labs, a German fertility startup, is developing therapies to rejuvenate aging eggs, potentially improving IVF success rates significantly.
– The startup’s technology aims to reduce genetic errors in eggs, increasing the likelihood of conception in a single IVF attempt and addressing the emotional and financial burdens of repeated IVF cycles.
– Led by Professor Melina Schuh and her team, the research builds on two decades of fertility studies, showing promising results in mice and isolated human eggs, though human trials await regulatory approval.
– The therapies target genetic abnormalities in eggs, which are prevalent in women over 40, aiming to restore egg quality and extend the reproductive window for couples.
– Ovo Labs has secured €4.6 million in funding to advance its research, with the potential to redefine IVF standards and offer new hope to those struggling with infertility.
A groundbreaking fertility startup is pioneering new methods to enhance human egg quality, potentially transforming IVF success rates for hopeful parents.
Based in Germany, Ovo Labs has developed innovative therapies designed to “rejuvenate” aging eggs, addressing one of the biggest challenges in reproductive medicine. The technology could significantly improve outcomes for women undergoing in vitro fertilization (IVF), a procedure that has helped millions conceive but often requires multiple attempts, or fails altogether.
IVF has revolutionized fertility treatment since the first successful birth over four decades ago. Yet despite its advancements, the process remains emotionally and financially taxing, with no guarantee of success. Many couples endure repeated cycles without achieving pregnancy. Ovo Labs aims to change that by reducing genetic errors in eggs, increasing the likelihood of conception in a single IVF attempt.
The startup’s approach builds on two decades of fertility research, led by co-founder Professor Melina Schuh, a renowned expert from the Max Planck Institute. Alongside her colleagues—Dr. Agata Zielinska and Dr. Oleksandr Yagensky—Schuh has demonstrated promising results in both aging mice and isolated human eggs. While human trials are still pending regulatory approval, the potential impact could redefine IVF standards.
“By improving egg viability, we hope to extend the reproductive window, giving more couples the chance to start a family when they’re ready,” Schuh explained.
The science behind Ovo Labs’ work stems from research conducted at Bourn Hall Clinic, the world’s first IVF center. Studies revealed that by age 40, over 70% of a woman’s eggs contain genetic abnormalities, drastically lowering conception odds. The startup’s therapies target these errors, aiming to restore egg quality and boost pregnancy success.
To accelerate development, Ovo Labs recently secured €4.6 million in funding, led by Creator Fund and LocalGlobe, with support from Blue Wire Capital and Ahren Innovation Capital. Jamie Macfarlane of Creator Fund praised the team’s mission, calling it a “solution to one of humanity’s most pressing challenges.”
While regulatory hurdles remain, the startup’s progress signals a potential breakthrough in fertility care. If successful, its treatments could offer new hope to millions struggling with infertility—turning the dream of parenthood into a more achievable reality.
A microscopic image of a human oocyte (egg cell), with DNA highlighted in pink, showcases the precision of Ovo Labs’ research.
(Source: The Next Web)